Fundraising Fox

Pyxis Oncology

NASDAQ: PYXS

Boston, US · Founded 2018 · 4 known investors

Find your way into Pyxis Oncology

Pyxis Oncology is a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, with its lead candidate targeting a fibronectin variant found in tumor tissue but not healthy tissue. The company is evaluating its lead therapy as a monotherapy and in combination with an immunotherapy agent in head and neck cancer and other solid tumors.

Healthtech

Founders & leadership

TC
Thomas CivikInterim Chief Executive Officer, Director

Board

DSDavid Steinberg
David Steinbergin𝕏Board directorGeneral Partner at Longwood Fund
CWChristoph Westphal
Christoph WestphalBoard directorCo-Founder & General Partner at Longwood Fund
GVGeeta Vemuri
Geeta VemuriinBoard directorManaging Partner, Founder at Agent Capital
JK
Jak KnowlesBoard directorVenture Advisor at Agent Capital
JF
John FlavinBoard director
LI
Lucio IannoneBoard director

Investors · 4

Agent CapitalWalthamvia Geeta Vemuri · board
Longwood FundBostonvia Christoph Westphal · board
RA CapitalBoston
RTW Investments L.P.reportedNew York

Funding

SEC filings, press & company announcements

$194.5M disclosed across 2 of 6 rounds · 1900–2026

  • Undisclosed amountprivate placementJul 2026 · 2 sources
    Source ↗
▶$172.5MraisedMar 2021 · 38 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher O?DonnellDirector
  • Gotham MakkerDirector
  • Lara SullivanExecutive Officer, Director
  • David SteinbergDirector
  • John FlavinDirector
  • Lucio IannoneDirector
  • Robert CraneExecutive Officer
  • Christian SchetterDirector
Offering amount
$172.5M
Amount sold
$172.5M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22MraisedJul 2019 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David SteinbergExecutive Officer, Director
  • Christoph WestphalDirector
  • John FlavinDirector
  • Lucio IannoneDirector
  • Geeta VemuriDirector
  • Jak KnowlesDirector
Offering amount
$22M
Amount sold
$22M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Pyxis Oncology files prospectus for 39.2M share sale by existing holdersscanx.trade · Aug 2026Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks.comtipranks.com · Aug 2026Pyxis Oncology (NASDAQ: PYXS) secures $50M raise amid rising losses and going-concern riskstocktitan.net · Aug 2026Pyxis Oncology (NASDAQ: PYXS) raises up to $114M in private placement to fund MICVO trialsstocktitan.net · Jul 2026Pyxis Oncology Secures $114M for MICVO Cancer Trialallsci.com · Jul 2026Pyxis Oncology raises $50 million in private placement By Investing.comca.investing.com · Jun 2026

Frequently asked questions

What does Pyxis Oncology do?
Pyxis Oncology is a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, with its lead candidate targeting a fibronectin variant found in tumor tissue but not healthy tissue. The company is evaluating its lead therapy as a monotherapy and in combination with an immunotherapy agent in head and neck cancer and other solid tumors.
Who are Pyxis Oncology's investors?
Pyxis Oncology's investors include Agent Capital, Longwood Fund, RA Capital, RTW Investments L.P..
How much funding has Pyxis Oncology raised?
Pyxis Oncology has disclosed $194.5M raised across 2 of its 6 known rounds.
Where is Pyxis Oncology headquartered?
Pyxis Oncology is headquartered in Boston, US.